Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 69CNS 56Sarcoma 35Genitourinary 31Thoracic 30Head & Neck 29Breast 23Lymphoid 21Gynecologic 19Other hematologic neoplasm 15Dermatologic 13Other solid neoplasm 3Myeloid 3Tumor-Agnostic 2Plasma cell 2Other 2NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 19lutetium Lu 177 dotatate 8Octreotide 8lanreotide 7pasireotide 6Temozolomide 6Sunitinib 6pembrolizumab 5gallium Ga 68 dotatate 5Positron Emission Tomography Computed Tomography 5surufatinib 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Magnetic Resonance Spectroscopy 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Radiation × NET × Clear all
NCT02402920 2026-03-10

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
83 enrolled 13 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡